6 Life Sciences Tools & Services Stocks to Sell Now

This week, the ratings of 6 Life Sciences Tools & Services stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Charles River Laboratories International, Inc. (CRL) slips from a B to a D this week. Charles River Laboratories International, Inc. is a global provider of services to accelerate the drug discovery and development process. For more information, get Portfolio Grader’s complete analysis of CRL stock.

PAREXEL International Corporation (PRXL) declines this week from a C to a D. PAREXEL International Corporation is a contract research and product launch organization. For more information, get Portfolio Grader’s complete analysis of PRXL stock.

This week, Luminex Corp’s (LMNX) rating worsens to a D from the company’s B rating a week ago. Luminex Corp develops, manufactures and markets biological testing technologies with applications throughout the clinical diagnostic and life science industries. The company also gets F’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of LMNX stock.

Fluidigm Corporation (FLDM) experiences a ratings drop this week, going from last week’s D to a F. Fluidigm Corporation develops, manufactures, and markets proprietary Integrated Fluidic Circuit systems. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLDM stock.

This is a rough week for ChromaDex Corporation (CDXC). The company’s rating falls to D from the previous week’s C. For more information, get Portfolio Grader’s complete analysis of CDXC stock.

Genetic Technologies Limited Sponsored ADR (GENE) is having a tough week. The company’s rating falls from a C to a D. Genetic Technologies Limited Sponsored ADR is a biotechnology company that practices advanced DNA genetic research and testing. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GENE stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/11/6-life-sciences-tools-services-stocks-to-sell-now/.

©2021 InvestorPlace Media, LLC